Table 5.
Variable | OR | B | 95% CI | p-Value |
---|---|---|---|---|
Age, years | ||||
⩾65 | Ref | |||
<65 | 1.115 | 0.109 | 0.464–2.679 | 0.808 |
Gender | ||||
Female | Ref | |||
Male | 1.257 | 0.229 | 0.658–2.402 | 0.489 |
Education status | ||||
Primary | Ref | |||
Secondary | 0.598 | -0.515 | 0.238–1.503 | 0.274 |
Graduation | 0.416 | -0.878 | 0.183–0.943 | 0.036 |
Not available | 1.446 | 0.369 | 0.611–3.421 | 0.402 |
BMI, kg/m2 | ||||
⩾25 | Ref | |||
<25 | 2.358 | 0.858 | 1.164–4.777 | 0.017 |
Comorbidities | ||||
Diabetes | Ref | |||
Absent | 0.826 | -0.191 | 0.358–1.907 | 0.654 |
Present | ||||
Respiratory disease | ||||
Absent | Ref | |||
Present | 0.534 | -0.627 | 0.184–1.554 | 0.250 |
Autoimmune disease | ||||
Absent | Ref | |||
Present | 0.759 | -0.276 | 0.290–1.987 | 0.574 |
No. of comorbidities | ||||
⩽2 | Ref | |||
>2 | 2.159 | 0.770 | 0.883–5.279 | 0.092 |
No. of concomitant medications | ||||
⩽2 | Ref | |||
>2 | 2.457 | 0.899 | 1.202–5.025 | 0.014 |
Age at diagnosis | ||||
Late onset (⩾40 years) | Ref | |||
Early onset (40 years) | 1.555 | 0.441 | 0.719–3.363 | 0.262 |
Type of monoclonal antibody | ||||
Fully human monoclonal antibody | Ref | |||
Humanized monoclonal antibody | 1.432 | 0.359 | 0.596–3.442 | 0.422 |
Length of treatment | ||||
Long term (⩾6 months) | Ref | |||
Short term (<6 months) | 9.180 | 2.217 | 4.909–17.165 | <0.001 |
Hospitalizations during treatment | ||||
No | Ref | |||
Yes | 1.838 | 0.609 | 0.868–3.894 | 0.112 |
OR: odds ratio; CI: confidence interval; B: regression coefficient.